UroGen Pharma Quarterly Cash Flow Statement
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.83-0.15 (-0.41%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma free cash flow
In the quarter ended Jun 30, 2026, UroGen Pharma generated -$33.0 million of operating cash flow and spent $60,000 on capital expenditures. That left free cash flow of -$33.1 million, a free-cash-flow margin of -45.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -14.35M | -23.57M | -26.36M | -33.35M | -49.94M | -43.84M | -37.51M | -23.67M | -33.40M | -32.29M | -26.02M | -21.88M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 100.00K | 75.00K | 75.00K | 100.00K | 100.00K | 72.00K | 68.00K | 100.00K | 100.00K | 123.00K | 190.00K | 200.00K |
| Stock-Based Compensation | 5.33M | 4.63M | 3.13M | 3.03M | 2.73M | 3.07M | 3.30M | 3.49M | 3.56M | 2.76M | 2.61M | 2.22M |
| Change in Working Capital | -25.66M | -24.02M | -22.51M | -6.12M | 2.02M | 1.05M | 13.82M | -11.45M | 423.00K | 1.13M | 4.95M | -2.99M |
| Operating Cash Flow | -33.01M | -45.32M | -38.33M | -42.27M | -39.83M | -42.02M | -13.62M | -27.66M | -23.75M | -31.73M | -13.00M | -17.30M |
| Capital Expenditures | -60.00K | -54.00K | -17.00K | -87.00K | -141.00K | -44.00K | -115.00K | -96.00K | -84.00K | 0 | -56.00K | -100.00K |
| Investing Cash Flow | 1.67M | -20.69M | 27.72M | 31.40M | 28.41M | -25.96M | 60.62M | -106.75M | 12.00M | 13.52M | -11.34M | 401.00K |
| Debt Issued | 0 | 65.35M | 0 | 0 | 0 | 0 | 0 | — | — | — | 0 | 0 |
| Financing Cash Flow | 500.00K | 65.20M | 31.32M | 8.27M | 296.00K | 34.00K | 71.00K | 39.61M | 100.28M | 54.66M | 40.00K | 116.08M |
| Net Change in Cash | -30.83M | -800.00K | 20.71M | -2.60M | -11.12M | -67.95M | 47.07M | -94.81M | 88.53M | 36.44M | -24.30M | 99.18M |
| Free Cash Flow | -33.07M | -45.37M | -38.34M | -42.36M | -39.97M | -42.07M | -13.73M | -27.76M | -23.83M | -31.73M | -13.05M | -17.40M |
This table shows 12 quarterly periods of UroGen Pharma's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow URGN's reporting calendar. What is a cash flow statement?